Insider Transactions Reported by 38 Insiders of Xilio Therapeutics, Inc.

Symbol
XLO on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

Xilio Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
GILEAD SCIENCES, INC. 10%+ Owner $21,601,543 +$1,999,991 +10% 13 Feb 2026
Yekaterina Chudnovsky 10%+ Owner $5,320,000 07 Jun 2024
SV7 Impact Medicine Fund LP 10%+ Owner $2,678,630 26 Oct 2021
Bain Capital Life Sciences Investors, LLC 10%+ Owner $2,328,493 08 Dec 2021
James E. Flynn Possible Member of 10% Group, 10%+ Owner $1,898,994 26 Oct 2021
Atlas Venture Fund XI, L.P. 10%+ Owner $1,762,629 08 Feb 2024
FMR LLC Other* $1,583,366 26 Oct 2021
TAKEDA PHARMACEUTICAL CO LTD 10%+ Owner $1,224,350 26 Oct 2021
RiverVest Venture Fund IV, L.P. 10%+ Owner $1,196,399 26 Oct 2021
Rock Springs Capital Management LP 10%+ Owner $1,042,872 26 Oct 2021
BAY CITY CAPITAL LLC 10%+ Owner $937,477 26 Oct 2021
Merck KGaA 10%+ Owner $565,085 26 Oct 2021
Rene Russo PRESIDENT AND CEO, Director $372,363 +$24,680 +7.1% 31 Dec 2025
FIL Ltd Other* $181,525 26 Oct 2021
Alexandria Venture Investments, LLC 10%+ Owner $138,131 26 Oct 2021
Simon M. Tomlinson 10%+ Owner $108,827 21 Oct 2021
John Charles Williams 10%+ Owner $83,066 21 Oct 2021
Of Ulrich Rodeck Estate 10%+ Owner $83,066 21 Oct 2021
Timothy P. Clackson 10%+ Owner $75,493 21 Oct 2021
Christopher James Frankenfield Chief Financial Officer $73,107 -$4,522 -5.8% 31 Dec 2025
Katarina Luptakova Chief Medical Officer $73,002 31 Dec 2025
James Samuel Shannon Director $48,202 +$48,085 +41098% 16 Jun 2025
Kevin M. Brennan Svp, Finance And Accounting $19,697 -$1,174 -5.6% 31 Dec 2025
Rachel Humphrey Director $7,839 21 Oct 2021
Michael Jay Ross Director 15 Jun 2022
Edward C. English Principal Accounting Officer 01 Jan 2023
Martin H. Huber Jr. President And Head Of R&D 16 Aug 2023
Salvatore Giovine Chief Financial Officer 22 Feb 2022
Daniel Lynch Director, 10%+ Owner 21 Oct 2021
Daniel J. Curran Director 11 Jun 2025
Paul J. Clancy Director 11 Jun 2025
Aoife Brennan Director 11 Jun 2025
Sara Bonstein Director 11 Jun 2025
Akintunde Olatokumbo Bello Director 10 Jun 2025
Christina Rossi Director 11 Jun 2025
Robert W. Ross Director 11 Jun 2025
Tomas J. Heyman Director 12 Jun 2023
Yuan Xu Director 11 Jun 2025

Recent Insider Transactions by Companies or Individuals for Xilio Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Gilead Sciences, Inc. XLO Prefunded Warrants (right to buy) Purchase 10.2% 3,739,000 40,384,266 13 Feb 2026 Direct
Kevin M. Brennan XLO Common Stock Sale -22.3% $1,174 $0.6432 -1,826 6,371 02 Jan 2026 Direct
Christopher James Frankenfield XLO Common Stock Sale -22.1% $4,522 $0.6432 -7,030 24,766 02 Jan 2026 Direct
Katarina Luptakova XLO Common Stock Options Exercise 100% 16,625 33,250 01 Jan 2026 Direct
Katarina Luptakova XLO Restricted Stock Units Options Exercise -33.3% -16,625 33,250 01 Jan 2026 Direct
Kevin M. Brennan XLO Common Stock Options Exercise 156.4% 5,000 8,197 01 Jan 2026 Direct
Kevin M. Brennan XLO Restricted Stock Units Options Exercise -33.3% -5,000 10,000 01 Jan 2026 Direct
Christopher James Frankenfield XLO Common Stock Options Exercise 156% 19,375 31,796 01 Jan 2026 Direct
Christopher James Frankenfield XLO Restricted Stock Units Options Exercise -33.3% -19,375 38,750 01 Jan 2026 Direct
Rene Russo XLO Common Stock Options Exercise 15.7% 44,250 325,422 01 Jan 2026 Direct
Rene Russo XLO Restricted Stock Units Options Exercise -33.3% -44,250 88,500 01 Jan 2026 Direct
Katarina Luptakova XLO Stock Option (right to buy) Award 451,885 451,885 31 Dec 2025 Direct
Kevin M. Brennan XLO Stock Option (right to buy) Award 95,221 95,221 31 Dec 2025 Direct
Christopher James Frankenfield XLO Stock Option (right to buy) Award 668,789 668,789 31 Dec 2025 Direct
Rene Russo XLO Stock Option (right to buy) Award 1,500,258 1,500,258 31 Dec 2025 Direct
Gilead Sciences, Inc. XLO Series B Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security -100% -13,335,000 0 26 Nov 2025 Direct
Gilead Sciences, Inc. XLO Prefunded Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security 57.2% 13,335,000 36,645,266 26 Nov 2025 Direct
Kevin M. Brennan XLO Stock Option (right to buy) Disposed to Issuer -100% -100,000 0 21 Nov 2025 Direct
Kevin M. Brennan XLO Stock Option (right to buy) Award 231,700 131,700 21 Nov 2025 Direct
Christopher James Frankenfield XLO Stock Option (right to buy) Award -50% -155,090 155,090 21 Nov 2025 Direct
Christopher James Frankenfield XLO Stock Option (right to buy) Disposed to Issuer -100% -848,172 0 21 Nov 2025 Direct
Christopher James Frankenfield XLO Stock Option (right to buy) Award 1,618,082 925,000 21 Nov 2025 Direct
Katarina Luptakova XLO Stock Option (right to buy) Disposed to Issuer -100% -225,210 0 21 Nov 2025 Direct
Katarina Luptakova XLO Stock Option (right to buy) Award 850,210 625,000 21 Nov 2025 Direct
Rene Russo XLO Stock Option (right to buy) Disposed to Issuer -100% -2,198,212 0 21 Nov 2025 Direct
Rene Russo XLO Stock Option (right to buy) Award 4,273,212 2,075,000 21 Nov 2025 Direct
James Samuel Shannon XLO Common Stock Purchase 55.6% $17,215 $0.6886 25,000 70,000 17 Jun 2025 Direct
James Samuel Shannon XLO Common Stock Purchase $30,870 $0.6860 45,000 45,000 16 Jun 2025 Direct
Rene Russo XLO Common Stock Purchase 14.8% $24,680 $0.6801 36,289 281,172 16 Jun 2025 Direct
Robert W. Ross XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Aoife Brennan XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Sara Bonstein XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Daniel J. Curran XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Paul J. Clancy XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Yuan Xu XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
James Samuel Shannon XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Christina Rossi XLO Stock Option (right to buy) Award 31,000 31,000 11 Jun 2025 Direct
Akintunde Olatokumbo Bello XLO Stock Option (right to buy) Award 62,000 62,000 10 Jun 2025 Direct
Gilead Sciences, Inc. XLO Series C Warrants (right to buy) Purchase 13,335,000 13,335,000 05 Jun 2025 Direct
Gilead Sciences, Inc. XLO Series B Warrants (right to buy) Purchase 13,335,000 13,335,000 05 Jun 2025 Direct
Gilead Sciences, Inc. XLO Series A Warrants (right to buy) Purchase 13,335,000 13,335,000 05 Jun 2025 Direct
Gilead Sciences, Inc. XLO Prefunded Warrants (right to buy) Purchase 133.7% 13,335,000 23,310,266 05 Jun 2025 Direct
Rene Russo XLO Stock Option (right to buy) Award 190,000 190,000 15 Apr 2025 Direct
Christopher James Frankenfield XLO Stock Option (right to buy) Award 75,000 75,000 15 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.